Alligator Bioscience AB (FRA:7AL)
€ 0.0445 0.001 (2.3%) Market Cap: 36.64 Mil Enterprise Value: 33.37 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Alligator Bioscience AB at Biostock Life Science Summit (Virtual) Transcript

Nov 18, 2020 / NTS GMT
Release Date Price: €0.421561 (-1.93%)
Unidentified Participant

-- where our next presenter is Per Norlen, CEO of Alligator Bioscience. Welcome, Per.

Per Norlen
Alligator Bioscience AB - Chief Executive Officer

Thank you. All right. We're ready to go.

Unidentified Participant

Go ahead.

Per Norlen
Alligator Bioscience AB - Chief Executive Officer

So thank you so much. Alligator is a clinical stage public immuno-oncology biotech company. And I would like straight to the company highlights. So Alligator has generated five clinical stage programs built on our own technology platforms. We have a very strong innovation track record, and we brought them all the way from ID to clinical stage.

Today, we focus on two of these assets, lead asset assets that are moving into clinical Phase 2. And those two assets are optimized for best and first-in-class profile, and which is supported by a very strong preclinical and clinical package. We have also studies coming up already in 2021, and I will come back to this soon.

Also

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot